Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 1,616 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total value of $15,400.48. Following the completion of the sale, the executive vice president owned 155,913 shares of the company’s stock, valued at approximately $1,485,850.89. This represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Mark Eisner also recently made the following trade(s):

• On Wednesday, February 25th, Mark Eisner sold 1,889 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.82, for a total value of $18,549.98.
• On Monday, February 23rd, Mark Eisner sold 2,089 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $15,563.05.

Vir Biotechnology Stock Performance

Shares of NASDAQ:VIR traded down $0.68 during mid-day trading on Thursday, hitting $9.32. 21,297,575 shares of the company traded hands, compared to its average volume of 3,752,478. The firm’s 50 day simple moving average is $6.88 and its 200 day simple moving average is $6.02. The firm has a market cap of $1.30 billion, a P/E ratio of -2.95 and a beta of 1.69. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. The firm had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.Vir Biotechnology’s quarterly revenue was up 417.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.76) EPS. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on VIR. Evercore reiterated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Needham & Company LLC boosted their price target on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday. Barclays raised their price objective on Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Vir Biotechnology in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.89.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vir Biotechnology by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after acquiring an additional 1,390 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Vir Biotechnology during the third quarter worth $38,000. Raymond James Financial Inc. bought a new position in Vir Biotechnology during the second quarter worth $35,000. UMB Bank n.a. boosted its holdings in Vir Biotechnology by 1,418.7% in the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after purchasing an additional 6,597 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in Vir Biotechnology by 153.8% in the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas collaboration materially derisks VIR‑5500 and adds near‑term cash/validation — the global co‑development/co‑commercialization deal includes significant upfront/near‑term payments and up to large milestone upside, boosting the program’s commercial outlook. Astellas and Vir Biotechnology collaborate on VIR-5500
• Positive Sentiment: Updated Phase 1 data for VIR‑5500 show encouraging safety and activity (notable higher‑dose response rates), supporting the asset value that underpins the Astellas deal. VIR-5500 Phase 1 results
• Positive Sentiment: Quarterly beat and revenue surge: Q4 EPS topped estimates and revenue (~$64.1M) far exceeded consensus, helping justify higher analyst targets and fueling recent upside. Vir Q4 earnings highlights
• Positive Sentiment: Analyst support: Needham and other firms raised targets/ratings after the results and deal news, reinforcing bullish institutional views. Needham raises VIR price target
• Neutral Sentiment: Management will be highly visible to investors in March (TD Cowen, Leerink) — useful for clarification on milestones, commercialization plans and cash use. Investor conference participation
• Neutral Sentiment: Media and valuation pieces are amplifying interest and volume — increased coverage raises visibility but doesn’t change fundamentals alone. Valuation after collaboration & Phase 1 update
• Negative Sentiment: Public offering priced: Vir priced 17,647,058 shares at $8.50 (gross proceeds about $150M). Proceeds bolster the balance sheet but the issuance is dilutive and can pressure the stock near term. Public offering priced
• Negative Sentiment: Clustered insider selling: Multiple insiders (CEO, EVPs, CFO, CAO, a director) reported stock sales across Feb. 23–25 — increases visible supply and can weigh on sentiment despite company progress. Insider selling report
• Negative Sentiment: Ongoing losses: Despite revenue growth and partnership cash, Vir reported a sizable net loss and wide negative margins — long‑term upside depends on execution, milestones and commercial ramp. 2025 financial results

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.